2018 Press Releases


Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
December 3, 2018
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals In... More >>
November 30, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting
BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00 am Pacific Time) t... More >>
November 7, 2018
Xenon Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
BURNABY, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Stifel 2018 Healthcare Conference in N... More >>
November 6, 2018
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial r... More >>
October 30, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, Novemb... More >>
September 17, 2018
Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the closing of its previously announced public offering of 4,500,000 common shares pursuant to its existing shelf r... More >>
September 12, 2018
Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares
BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 4,500,000 common shares pursuant to its existing shelf registrat... More >>
September 12, 2018
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common shares pursuant to its existing shelf registrat... More >>
September 10, 2018
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
BURNABY, British Columbia, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced it has signed an agreement with Valeant Pharmaceuticals Luxembourg S.a.r.l. and Valeant Pharmaceuticals Ireland Lim... More >>
September 6, 2018
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
Single, Pivotal Phase 3 Clinical Trial in Approximately 20 KCNQ2-EE Patients Expected to be Initiated in Mid-2019 Conference Call Today at 8:00 am ET Xenon to Webcast Update on Epilepsy Pipeline from Biocentury NewsMakers Conference on September 7, 2018 BURNABY, British Columbia, Sept. 06, 2018 ... More >>
August 29, 2018
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
XEN1101 Demonstrates Statistically Significant Reduction in Corticospinal and Cortical Excitability as Measured by TMS-EMG and TMS-EEG XEN1101 Demonstrates Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Historical Ezogabine Data XEN1101 Phase 2 Cli... More >>
August 7, 2018
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Novel Epilepsy Product Candidates – XEN1101 and XEN901 – Continue to Advance in the Clinic New XEN1101 Phase 1b TMS Pharmacodynamic Data to be Presented at upcoming European Congress on Epileptology BURNABY, British Columbia, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq... More >>
August 3, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, Augus... More >>
July 12, 2018
Xenon Pharmaceuticals Announces At-The-Market Equity Offering
BURNABY, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, announced today that it has entered into an at-the-market equity offering sales agreement with Jefferies and Stifel, effective as of July 11, 2018, und... More >>
June 1, 2018
Xenon Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
BURNABY, British Columbia, June 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Jefferies 2018 Healthcare Conference i... More >>
May 15, 2018
Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold at Significantly Lower Dose When Compared to Ezogabine Phase 1 Pharmacokinet... More >>
May 15, 2018
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre-clinical Data Support Selective Nav1.6 Mechanism of Action and XEN901 Efficacy Su... More >>
May 14, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of XEN1101 and XEN901 Presentations at 14th Eilat Conference
BURNABY, British Columbia, May 14, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will provide a corporate update and overview of the presentations on its proprietary epilepsy products, XEN1101 and XEN901, at t... More >>
May 8, 2018
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Xenon’s novel clinical stage epilepsy candidates, XEN1101 and XEN901, to be presented at upcoming  14th Eilat Conference on New Antiepileptic Drugs and Devices on May 15, 2018 BURNABY, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage ... More >>
May 1, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results and Provide Corporate Update
BURNABY, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, ... More >>
April 25, 2018
Xenon Pharmaceuticals to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
BURNABY, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will present a corporate update at the Bloom Burton & Co. Healthcare Inv... More >>
March 28, 2018
Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partners L.P.
BURNABY, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported the closing of the previously announced transaction with Teva Pharmaceuticals International GmbH, along with Teva Canada Limited (colle... More >>
March 13, 2018
Dr. Ernesto Aycardi Joins Xenon Pharmaceuticals as Chief Medical Officer
Changes to Senior Leadership Support Expanding Neurology Pipeline BURNABY, British Columbia, March 13, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Ernesto Aycardi will join the company as its Chief Medical... More >>
March 7, 2018
Xenon Pharmaceuticals Reports 2017 Financial Results and Provides Corporate Update
Two novel anti-epileptic drugs advancing in clinical development; Interim XEN1101 Phase 1 data expected to be released in May 2018 at scientific symposium; Xenon announces new clinical stage ion channel product to expand its neurology pipeline BURNABY, British Columbia, March 07, 2018 (GLOBE ... More >>
February 28, 2018
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2017 Financial Results and Provide Corporate Update
BURNABY, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2017 financial and operating results after the close of U.S. financial markets on Wednesday, March 7, 2018.  Xe... More >>
February 20, 2018
Xenon Pharmaceuticals Advances Second Proprietary Epilepsy Product into the Clinic with Initiation of XEN901 Phase 1 Clinical Trial
BURNABY, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of its proprietary epilepsy product candidate, XEN901, which is an orally administered, smal... More >>
January 8, 2018
Xenon Pharmaceuticals Outlines Key Milestones for 2018
BURNABY, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key corporate milestones for 2018. Dr. Simon Pimstone, Xenon's President and Chief Ex... More >>